查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1972676

碘-131同位素市场：依产品类型、应用、最终用途及通路划分－2026-2032年全球预测

Iodine-131 Isotope Market by Product Type, Application, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，碘-131 同位素市场价值将达到 7.453 亿美元，到 2026 年将成长至 7.8867 亿美元，到 2032 年将达到 10.822 亿美元，复合年增长率为 5.47%。

主要市场统计数据
基准年 2025 7.453亿美元
预计年份：2026年 7.8867亿美元
预测年份 2032 1,082,200,000 美元
复合年增长率 (%) 5.47%

对碘-131的临床意义、供应和监管趋势以及营运重点进行策略概述，以支持短期相关人员的决策。

碘-131 仍然是一种核心放射性药物，在肿瘤学和甲状腺疾病治疗中具有持续的临床意义。近年来，其治疗效用、供应链运作中的薄弱环节以及日益严格的监管审查引起了广泛关注。这三个因素共同影响医疗服务提供者、生产者和支付方采购和临床整合的方式。在此背景下，相关人员需要明确整合临床适应症、生产方法和物流依赖关係，并将营运计画与患者照护的优先事项保持一致。

这定义了治疗创新、供应韧性、监管改革和营运现代化如何共同改变碘-131的使用和供应模式。

由于治疗、给药和监管方面的创新，碘-131领域正经历变革性的变化。在治疗方面，标靶给药方法和联合治疗的整合正在重塑临床通讯协定，并影响医疗机构多样化的需求。同时，放射性药物分发实践和自动化分发技术的进步正在改变医疗机构管理剂量准确性、职业安全和处理能力的方式。

本研究评估了美国在 2025 年征收的关税对碘-131的采购、分销经济和临床连续性计划的营运和战略影响。

2025年关税的征收和贸易政策的变化，已在放射性药物原材料和碘-131成品的现有供应链中造成了明显的营运摩擦，促使采购团队重新评估其筹资策略和总到岸成本结构。虽然关税只是一项政策工具，但其影响却波及生产经济、库存管理实践以及跨境临床供应等各个方面，因此生产商和供应商都需要采取战术性和战略应对措施。

实际的細項分析揭示了应用重点、产品形式、临床最终用户和通路如何共同塑造部署和商业化选择。

对市场细分的深入分析阐明了临床应用、产品配方、终端用户环境和通路如何全面决定产品的采用模式和营运重点。按应用领域划分，癌症治疗、医学影像和甲状腺治疗的临床需求各不相同。在癌症治疗领域，联合治疗和标靶治疗通讯协定又有差异，每种方案都对应不同的给药方案、频率需求和医护人员准备要求。

从区域观点来看，我们将详细分析美洲、欧洲、中东、非洲和亚太地区的准入便利因素、监管差异、供应基地和投资环境。

区域趋势对碘-131的取得、监管复杂性和供应结构起着至关重要的作用。在美洲，完善的临床网络和成熟的放射性药物分发能力支持其在三级医疗机构的广泛应用；然而，地理分​​散导致部分地区获取受限，因此需要进行物流创新并采用中心辐射式分销模式。该地区的需求模式受到不断变化的临床指南和报销政策的影响，这些因素决定了治疗用途和诊断用途之间的优先顺序。

主要企业层面深入了解製造实力、以服务为中心的差异化、策略伙伴关係以及塑造碘-131领导地位的竞争优势。

在企业层面，发展趋势体现在核心製造能力、专业放射化学技术和服务导向能力的整合，这些因素决定了企业的竞争地位。主要企业优先考虑稳定采购前驱材料、投资建置符合GMP规范的放射性药物生产线，并实施先进的品质管理系统以满足监管要求。同时，一些企业透过提供承包放射性药物服务、临床试验支援和物流伙伴关係等增值服务来减轻终端用户的负担，从而实现差异化竞争。

为产业领导者提供切实可行的优先建议，以加强供应链韧性、加速临床部署并降低监管和营运风险。

产业领导者应共同采取一系列战术性和策略行动，以增强供应链韧性，支持临床应用，并应对监管和成本压力。首先，应优先投资于供应链的透明度和冗余性，具体措施包括认证替代前体供应商和製定应急生产计画。整合以场景为基础的库存管理将减少服务中断，保障临床工作的连续性。其次，应透过培训、标准化製备通讯协定和资本资金筹措模式，支持胶囊剂、注射和液体製剂的工作流程，使产品剂型策略与医疗服务提供者的能力相符。

高度透明且可重复的调查方法：结合与专家的直接对话、整合二手证据、实地检验和分析三角测量。

本分析的调查方法结合了结构化的专家访谈和全面的二手证据审查，以确保研究的深度和有效性。主要访谈对象包括临床医生、放射性药物管理人员、生产管理人员和物流专家，他们提供了关于临床通讯协定、营运限制和供应链紧急应变计画的直接见解。除了这些定性访谈外，还进行了现场考察和流程审核，以观察实际的药品分发流程和低温运输操作。

为了向相关人员提供了解碘-131现状的指南，本文檔提出了一个简明的结论，整合了策略要求、营运风险和机会创造途径。

总之，碘-131占据着一个关键的市场定位，治疗需求与物流复杂性在此交汇，因此相关人员需要采取综合策略，以确保患者能够持续获得治疗。治疗创新、供应链重组以及日益严格的监管要求，既带来了风险，也带来了机会。那些积极提升生产可靠性、调整产品形式以适应临床工作流程并与监管机构和供应商合作的机构，将更有利于创造价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：碘-131同位素市场：依产品类型划分

  • 胶囊
  • 注射药物
    • 预填充式注射器
    • 管瓶
  • 液体溶液

第九章：碘-131同位素市场：依应用领域划分

  • 癌症治疗
    • 联合治疗
    • 标靶治疗
  • 医学影像诊断
  • 甲状腺治疗

第十章：碘-131同位素市场：依最终用途划分

  • 诊断中心
  • 医院
  • 研究机构

第十一章 碘-131同位素市场：依分销管道划分

  • 直销
  • 销售代理

第十二章 碘-131同位素市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 碘-131同位素市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 碘-131同位素市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国碘-131同位素市场

第十六章：中国碘-131同位素市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Accelerator Applications SA
  • China Isotope & Radiation Corporation
  • Curium Pharma SAS
  • Eckert & Ziegler Radiopharma GmbH
  • Institute for Radioelements SCRL
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Mallinckrodt plc
  • Nordion Inc.
  • NorthStar Medical Radioisotopes LLC
  • NorthStar Medical Radioisotopes LLC
Product Code: MRR-9A6A6F297712

The Iodine-131 Isotope Market was valued at USD 745.30 million in 2025 and is projected to grow to USD 788.67 million in 2026, with a CAGR of 5.47%, reaching USD 1,082.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 745.30 million
Estimated Year [2026] USD 788.67 million
Forecast Year [2032] USD 1,082.20 million
CAGR (%) 5.47%

Strategic overview of iodine-131 clinical relevance, supply and regulatory dynamics, and operational priorities that inform near-term stakeholder decision making

Iodine-131 remains a cornerstone radiopharmaceutical with enduring clinical relevance across oncology and thyroid care. Recent years have seen an intensification of attention on its therapeutic utility, operational fragility in supply chains, and regulatory scrutiny that together shape how providers, manufacturers, and payers approach procurement and clinical integration. Against this backdrop, stakeholders require a clear synthesis of clinical indications, manufacturing modalities, and logistical dependencies to align operational plans with patient care priorities.

This introduction situates iodine-131 within a broader convergence of therapeutic innovation and health system resource constraints. It highlights emerging procedural norms and technological enablers that influence utilization patterns, while emphasizing supply continuity as a strategic risk that demands proactive mitigation. Moreover, by framing current dynamics in relation to evolving regulatory expectations and clinical trial activity, the introduction prepares readers to navigate trade-offs between access, safety, and scalability.

In practical terms, this section orients leaders to the core levers that will determine near-term decision making: clinical demand drivers, manufacturing and distribution realities, and the regulatory pathways shaping product availability. It establishes a foundation for the deeper analyses that follow and underscores the imperative of integrated, cross-functional responses to sustain patient access and institutional readiness.

Defining how therapeutic innovation, supply resilience, regulatory reform, and operational modernization are jointly transforming iodine-131 utilization and delivery models

The iodine-131 landscape is undergoing transformative shifts driven by innovation at the therapeutic, operational, and regulatory margins. On the therapeutic front, integration of targeted delivery approaches and combination regimens is reshaping clinical protocols and influencing demand heterogeneity across care settings. At the same time, developments in radiopharmacy practice and automated dispensing technologies are altering how facilities manage dosing accuracy, occupational safety, and throughput.

Operationally, supply chain resilience has moved from a desirable attribute to a core strategic objective. Multi-node sourcing strategies, investments in onshore or regional production capacity, and strengthened cold-chain capabilities are becoming essential responses to episodic interruptions. Concurrently, regulators are tightening oversight around radiopharmaceutical manufacturing standards and traceability, prompting organizations to increase compliance investments and to adopt more robust quality management systems.

These shifts are not isolated; they interact in ways that create new value pathways. For instance, therapeutic innovations that reduce required dose or frequency can ease logistical pressure, while improved distribution practices accelerate clinical access and reduce waste. Therefore, leaders must consider cross-functional interventions that link clinical development, operations, and regulatory engagement to realize sustained improvements in availability and patient outcomes.

Assessing the operational and strategic consequences of United States tariffs in 2025 on iodine-131 sourcing, distribution economics, and clinical continuity planning

The imposition of tariffs and trade policy changes in 2025 introduced measurable operational friction into established supply chains for radiopharmaceutical inputs and finished iodine-131 products, prompting procurement teams to reassess sourcing strategies and total landed cost structures. Although tariffs are a single policy lever, their effects cascade across manufacturing economics, inventory practices, and cross-border clinical provisioning, necessitating tactical and strategic responses from producers and providers alike.

In immediate operational terms, organizations adjusted procurement rhythms, increased holding inventory where feasible, and explored alternate sourcing geographies to maintain continuity of care. These actions, in turn, reshaped distribution timelines and elevated the importance of contractual flexibility and inventory visibility. From a strategic perspective, the tariff environment accelerated conversations about regional production capacity and vertical integration to reduce exposure to transnational cost shocks.

Importantly, these responses varied by institutional capability. Larger health systems and specialized manufacturers with deep supply networks adapted more rapidly through diversified procurement and inventory management, while smaller centers faced greater pressure to negotiate supplier terms or to collaborate through purchasing consortia. Going forward, resilience planning must factor tariff volatility into capital allocation, contractual design, and collaborative frameworks that preserve patient access amid evolving trade dynamics.

Actionable segmentation insights revealing how application focus, product form, clinical end users, and distribution pathways combine to shape deployment and commercialization choices

A granular view of market segmentation clarifies how clinical application, product formulation, end-user environment, and distribution pathways collectively determine adoption patterns and operational priorities. When examined by application, clinical demand differentiates across cancer therapy, medical imaging, and thyroid treatment; within cancer therapy, there is further delineation between combination therapy approaches and targeted therapy protocols, each driving distinct dosing regimens, frequency expectations, and provider readiness requirements.

Product-type segmentation further refines logistical and regulatory considerations. Capsules, injectable formats, and liquid solutions each impose unique handling and dispensing protocols; specifically, injectable formats bifurcate into prefilled syringe presentations and vial-based delivery, with implications for sterility controls, occupational safety procedures, and on-site preparation workflows. These product distinctions dictate cold-chain needs, pharmacy staffing models, and capital investments in dispensing equipment.

End-use contexts-diagnostic centers, hospitals, and research institutes-exhibit varied operational capabilities and procurement models that influence inventory practices and clinical throughput. Distribution channel dynamics, whether through direct sales relationships or distributor networks, shape contractual terms, lead-time expectations, and the scope of after-sales support. Taken together, these segmentation lenses inform targeted go-to-market strategies, clinical training priorities, and infrastructure investments that align product form and channel to institutional capability.

Tailored regional perspectives highlighting access drivers, regulatory variation, supply hubs, and investment climates across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a decisive role in access, regulatory complexity, and supply architecture for iodine-131. In the Americas, robust clinical networks and established radiopharmacy capabilities support concentrated usage in tertiary centers, but geographic dispersion creates pockets of access constraint that require logistical innovation and hub-and-spoke distribution models. Demand patterns in this region are influenced by evolving clinical guidelines and reimbursement practices that drive prioritization of therapeutic versus diagnostic use cases.

Moving to Europe, Middle East & Africa, regulatory fragmentation and variable infrastructure maturity create heterogeneity in clinical adoption and supply reliability. In several European markets, well-established nuclear medicine programs coexist with regulatory frameworks that emphasize pharmacovigilance and manufacturing traceability, whereas parts of the Middle East and Africa are actively investing in capacity building to reduce import dependence and to enhance local clinical capabilities. Cross-border collaboration and regional centers of excellence are emerging mechanisms to address uneven access.

Across Asia-Pacific, rapid clinical expansion in oncology services, significant investment in local manufacturing, and a dynamic regulatory environment are accelerating adoption in both public and private systems. However, disparities in facility-level readiness and cold-chain infrastructure mean that regional strategies must be calibrated to local logistical realities. Collectively, regional variation underscores the need for differentiated commercial approaches and targeted capacity-building initiatives that respect regulatory and operational context.

Key company-level insights into manufacturing strengths, service-centric differentiation, strategic alliances, and competitive levers shaping iodine-131 leadership

Company-level dynamics reflect a blend of core manufacturing competencies, specialized radiochemistry expertise, and service-oriented capabilities that determine competitive positioning. Leading manufacturers have prioritized secure sourcing of precursor materials, investments in GMP-compliant radiopharmaceutical production lines, and implementation of advanced quality systems to satisfy regulatory scrutiny. Concurrently, some organizations have differentiated through extended service offerings such as turnkey radiopharmacy operations, clinical trial support, and logistics partnerships that reduce friction for end users.

Contract manufacturing organizations and specialized nuclear medicine firms have expanded collaboration models with healthcare providers to offer integrated solutions that combine supply, training, and onsite preparation. This shift from pure product supply toward service-enabled partnerships enhances stickiness with major hospital systems and diagnostic networks. At the same time, smaller niche players continue to innovate in formulation and dispensing technologies, offering modular solutions that target specific clinical workflows or resource-constrained settings.

Strategic alliances, including partnerships with logistics specialists and clinical networks, have become common as companies seek to manage distribution complexity and to scale access. Intellectual property management, regulatory track records, and the ability to execute reliable batch production remain central determinants of competitive advantage in this specialized domain.

Practical and prioritized recommendations for industry leaders to reinforce supply resilience, accelerate clinical adoption, and mitigate regulatory and operational risks

Industry leaders should adopt a coordinated set of tactical and strategic actions to strengthen supply resilience, support clinical uptake, and manage regulatory and cost pressures. First, prioritize investments in supply chain visibility and redundancy by qualifying alternate suppliers of precursors and by developing contingency production plans; integrating scenario-based inventory management will reduce service disruptions and protect clinical continuity. Second, align product-format strategies with provider capabilities by supporting capsule, injectable, and liquid solution workflows through training, standardized preparation protocols, and equipment financing models.

Third, engage proactively with regulatory agencies and professional societies to shape pragmatic compliance pathways that safeguard patient safety while reducing administrative friction. Fourth, pursue collaborative service models that bundle supply with technical assistance-such as on-site radiopharmacy consulting, dosing optimization, and safety training-to increase value to end users and to deepen commercial relationships. Fifth, explore regional manufacturing partnerships or licensing arrangements to reduce cross-border exposure and to leverage local regulatory approvals for faster clinical deployment.

Finally, invest in data-driven post-market surveillance and real-world evidence generation that documents clinical outcomes and supports payer conversations. These measures, taken together, will improve predictability, enhance clinical integration, and create defensible competitive positioning in a resource-constrained, highly regulated environment.

Transparent and reproducible research methodology blending primary expert engagement, secondary evidence synthesis, site-level validation, and analytical triangulation

The research methodology underpinning this analysis combined structured primary engagement with domain experts and a comprehensive secondary evidence review to ensure depth and validity. Primary inputs included interviews with clinicians, radiopharmacy managers, manufacturing leaders, and logistics specialists who provided firsthand perspectives on clinical protocols, operational constraints, and supply contingencies. These qualitative engagements were complemented by site visits and process audits to observe dispensing workflows and cold-chain practices in situ.

Secondary research synthesized regulatory guidance, peer-reviewed clinical literature, manufacturing standards, and publicly available clinical trial registries to triangulate trends and to validate operational hypotheses. Additionally, patent landscapes and technical white papers informed assessments of formulation and dispensing innovations. Analytical frameworks emphasized cross-functional triangulation, ensuring that clinical demand signals, production realities, and distribution constraints were considered in concert.

Validation steps included peer review from independent subject-matter experts and cross-checks against published clinical guidelines and regulatory documents. Where possible, findings were corroborated through multiple sources to reduce bias. The methodology prioritized transparency, reproducibility, and a clear audit trail for key assertions, enabling stakeholders to understand the evidence base behind strategic recommendations.

Concise conclusion synthesizing strategic imperatives, operational risks, and opportunity pathways to guide stakeholders through the iodine-131 landscape

In conclusion, iodine-131 occupies a critical niche at the intersection of therapeutic need and logistical complexity, and stakeholders must adopt integrated strategies to ensure sustained patient access. The convergence of therapeutic innovation, supply chain rebalancing, and heightened regulatory expectations creates both risk and opportunity; organizations that proactively shore up manufacturing reliability, align product forms to clinical workflows, and engage collaboratively with regulators and providers will be best positioned to deliver value.

Moreover, regional diversity in infrastructure and regulatory approaches requires tailored responses that combine targeted investments with partnership models that scale capability efficiently. Companies that develop service-enabled offerings and that invest in real-world evidence to substantiate clinical benefits will enhance adoption and deepen institutional relationships. Finally, resilient procurement practices, scenario-based planning for policy shifts, and investments in operational excellence will collectively reduce vulnerability to supply shocks and policy changes.

Taken together, these priorities form a pragmatic roadmap for sustaining and expanding access to iodine-131 therapies and diagnostics while managing cost and compliance considerations in an increasingly complex global environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Iodine-131 Isotope Market, by Product Type

  • 8.1. Capsule
  • 8.2. Injectable
    • 8.2.1. Prefilled Syringe
    • 8.2.2. Vial
  • 8.3. Liquid Solution

9. Iodine-131 Isotope Market, by Application

  • 9.1. Cancer Therapy
    • 9.1.1. Combination Therapy
    • 9.1.2. Targeted Therapy
  • 9.2. Medical Imaging
  • 9.3. Thyroid Treatment

10. Iodine-131 Isotope Market, by End Use

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Iodine-131 Isotope Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors

12. Iodine-131 Isotope Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Iodine-131 Isotope Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Iodine-131 Isotope Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Iodine-131 Isotope Market

16. China Iodine-131 Isotope Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Accelerator Applications S.A.
  • 17.6. China Isotope & Radiation Corporation
  • 17.7. Curium Pharma SAS
  • 17.8. Eckert & Ziegler Radiopharma GmbH
  • 17.9. Institute for Radioelements SCRL
  • 17.10. Jubilant Pharma Limited
  • 17.11. Lantheus Holdings, Inc.
  • 17.12. Mallinckrodt plc
  • 17.13. Nordion Inc.
  • 17.14. NorthStar Medical Radioisotopes LLC
  • 17.15. NorthStar Medical Radioisotopes LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IODINE-131 ISOTOPE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IODINE-131 ISOTOPE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY MEDICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY MEDICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY MEDICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY THYROID TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY THYROID TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY THYROID TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. GCC IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. G7 IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. NATO IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL IODINE-131 ISOTOPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA IODINE-131 ISOTOPE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY CANCER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA IODINE-131 ISOTOPE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)